Organisation › Details

Autolus Therapeutics plc (Nasdaq: AUTL)

Autolus is a private biopharmaceutical company, focused on the development and commercialisation of engineered T-cell immunotherapy products based on its proprietary T-cell programming technology. Autolus’ shareholders include Syncona LLP, UCL Business PLC, Woodford Investment Management LLP and Perceptive Bioscience Investments Ltd. *

 

Period Start 2018-06-22 renamed
  Predecessor Autolus Therapeutics Ltd.
Products Industry BIOTECH
  Industry 2 T cell therapy
Persons Person Itin, Christian (Autolus 201603– CEO before Cytos 201211–201601 + Micromet 1999–2012 CEO + Co-founder + Zyomyx Inc)
  Person 2 Oakley, Andrew J. (Autolus 201806– CFO before Sosei + Vectura + Novimmune + Actelion)
     
Region Region London, Greater London
  Country United Kingdom (GB)
  Street 58 Wood Lane
  City W12 7RP London
  Tel +44-20-3829-6230
    Address record changed: 2018-06-28
     
Basic data Employees n. a.
     
    * Document for �About Section�: Autolus Therapeutics Ltd.. (3/3/16). "Press Release: Autolus Limited Secures £40 Million Funding – Woodford Investment Management and Perceptive Bioscience Complete Series B Financing". London.
     
   
Record changed: 2019-02-19

Advertisement

Picture [LSUK] Life-Sciences-UK.com – The Business Web Portal 650x99px

More documents for Autolus Therapeutics plc (Nasdaq: AUTL)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture [iito] – Putting Information into Context 600x60px




» top